Weis announces quarterly dividend, offers one-time special dividend to shareholders
SUNBURY, Pa. — Weis Markets’ board of directors on Thursday declared a quarterly dividend of 30 cents to.
In addition to the 30-cent dividend, the board also offered a special one-time dividend valued at $1 per share as a reward to shareholders, Weis chairman Robert Weis said. The special dividend will be paid to shareholders of record as of Nov. 7 and payable on Nov. 12.
Weis added that the company’s $100 million 2011 capital expansion plan is 75% complete.
Publix to offer Adheris medication education, adherence programs to pharmacy customers
BURLINGTON, Mass. — Publix has partnered with Adheris, an inVentiv Health company, to provide medication education and adherence programs to Publix pharmacy customers.
"As a neighborhood pharmacy, we are uniquely positioned to provide information on health and wellness to our customers," Publix director of media and community relations Maria Brous said. "As part of the patient-pharmacist relationship, we also want our customers to remain compliant with their medications to promote the benefits of healthy living. Our partnership with Adheris reinforces our commitment to overall customer service and education."
According to the New England Healthcare Institute, medication nonadherence costs the U.S. healthcare system an estimated $290 billion annually.
Publix currently operates more than 1,000 supermarkets and 800 pharmacies.
Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment
FOSTER CITY, Calif. — Drug makers Bristol-Myers Squibb and Gilead Sciences announced an agreement to develop and commercialize a fixed-dose combination treatment for patients with HIV.
The two companies said the drug will combine Bristol’s Reyataz (atazanavir sulfate) and Gilead’s boosting agent cobicistat, which is designed to increase blood levels of certain HIV medicines to potentially allow for one-pill, once-daily dosing. Gilead is currently studying Reyataz and cobicistat in phase-2 and phase-3 trials.
"This collaboration with Gilead builds on Bristol-Myers Squibb’s long-standing commitment to develop medicines that have the potential to improve meaningful benefit to HIV patients, specifically aiming to enhance treatment options," Bristol EVP, chief scientific officer and president for research and development Elliott Sigal said. "A Reyataz and cobicistat fixed-dose combination has the potential not only to help simplify HIV therapy but also to address an unmet medical need in HIV for additional, innovative treatment options."